Incidence & assessment of tranexamic acid in reducing postpartum bleeding in pre eclampsia patients undergoing LSCS

Effect of tranexamic acid in reducing postpartum bleeding in pre-eclampsia patients undergoing lower segment caesarean section: A Randomised Controlled Trial - ETPBPE

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/10/059089

Enrollment

Registered

2023-10-25

Start date

Unknown

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O72- Postpartum hemorrhage

Interventions

Intervention1: Effect of tranexamic acid in reducing postpartum bleeding in pre eclampsia patients undergoing lower segment caesarian section: Use of 1 gm of tranexamic acid in reducing postpartum bl

Eligibility

Inclusion criteria

Inclusion criteria: Pregnant women with period of gestation 37-42 weeks with documented pre-eclampsia as per ACOG criteria

Exclusion criteria

Exclusion criteria: moderate anemia (Hb Patient on anticoagulation, Eclampsia, ASA III & IV

Design outcomes

Primary

Measure	Time frame
1. To evaluate the effects of tranexamic acid on blood loss in patients with pre eclampsia undergoing LSCS Timepoint: post-operative period within 48 hours	—

Secondary

Measure	Time frame
1. To evaluate the effect of tranexamic acid on the incidence of PPH in patients with pre-eclampsia patients undergoing LSCS. 2. To evaluate the effect of tranexamic acid on the requirement of blood & blood products in pre-eclampsia patients undergoing LSCS. 3. To evaluate the effect of tranexamic acid on the Haemoglobin in pre-eclampsia patients undergoing LSCS. 4. To evaluate the safety of tranexamic acid in patients with pre-eclampsia undergoing LSCS. Timepoint: post-operative period within 48 hours	—

Measure

Time frame

1. To evaluate the effect of tranexamic acid on the incidence of PPH in patients with pre-eclampsia patients undergoing LSCS. 2. To evaluate the effect of tranexamic acid on the requirement of blood & blood products in pre-eclampsia patients undergoing LSCS. 3. To evaluate the effect of tranexamic acid on the Haemoglobin in pre-eclampsia patients undergoing LSCS. 4. To evaluate the safety of tranexamic acid in patients with pre-eclampsia undergoing LSCS. Timepoint: post-operative period within 48 hours

—

Countries

India

Contacts

Public ContactAniruddh Kripal singh

Command Hospital, Lucknow

drbadalparikh@gmail.com7073088722

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026